Navigation Links
The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research

Virtual March Connects 'IBD Day on the Hill' Advocates in Washington, D.C. with Online Supporters

PHILADELPHIA, May 6 /PRNewswire-FirstCall/ -- Today the Crohn's & Colitis Foundation of America (CCFA) and Shire plc (LSE: SHP, Nasdaq: SHPGY) joined forces to launch the first-ever virtual "Inflammatory Bowel Disease (IBD) March on the Hill." The free program calls on Facebook(R) users to help raise awareness of IBD and spurs funds for additional research of the disease.

To participate in the virtual "IBD March on the Hill," Facebook users can visit and, with the click of a mouse, take a virtual "step" around the National Mall in Washington, DC. Users will be asked to choose a unique shoe to place on the track and will see how their step has impacted the total number of steps taken to date. Shire will donate $1 per footstep to CCFA for research, education and support initiatives for each of the first 30,000 steps taken.

In addition to raising funds for IBD research, the virtual march gives those affected by IBD the opportunity to support the more than 75 patient advocates who are in Washington, DC today for CCFA's seventh National Advocacy Conference "IBD Day on the Hill." The advocates will meet with legislators to gain support for the IBD Research and Awareness Act.

"We are thrilled to extend our advocacy on the Hill to the online community," said Gary Sinderbrand, the chairman of CCFA's National Board of Trustees. "We have made it a point to provide a specific resource for the IBD patient community on Facebook through our new CCFA Facebook Page ( and now we're asking supporters to join us 'virtually' in DC. With this community support, we are one step closer to increasing education and research for IBD."

After the 30,000 steps have been reached, the program will continue to generate awareness of CCFA's efforts to rally advocates to increase awareness of IBD.

"We are excited to work with CCFA to launch an innovative program that engages IBD patients, friends and family members through social networking to increase IBD awareness and research," said Roger Adsett, senior vice president of Shire's gastrointestinal business unit. "We hope this program will continue to demonstrate our commitment to providing education to the IBD patient community and support for CCFA's advocacy efforts on Capitol Hill."

For more information on the virtual "IBD March on the Hill" or CCFA's "IBD Day on the Hill," visit

For further information please contact:

    Media    Sarah McGee (GolinHarris)                        +1 312 729 4125
             Matthew Cabrey (Shire)                           +1 484 595 8248
             Ariella Levine (Crohn's & Colitis Foundation)    +1 646 943 7430

About Crohn's Disease & Ulcerative Colitis

Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's disease or ulcerative colitis, with as many as 150,000 under the age of 18. Most people develop the diseases between the ages of 15 and 35.

About the Crohn's & Colitis Foundation of America (CCFA)

The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 81 cents of every dollar the Foundation spends going to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance ( and the American Institute of Philanthropy ( For more information, contact the Foundation at 800-932-2423 or visit


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products;

and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis
2. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
3. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
4. Elsevier and Brain Mapping Foundation Co-Host 6th Annual World Congress of IBMISPS on Brain Mapping and Image Guided Therapy
5. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
6. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
7. Mirixa Corporation and the APhA Foundation Finalize Partnership
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation
10. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
11. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
Post Your Comments:
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
Breaking Biology News(10 mins):